{"analyses":[{"ciLowerLimit":"0.465","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.723","estimateComment":"HR from Cox proportional hazards model stratified by age (18 - \\< 75, ≥ 75) and cytogenetic risk (intermediate, poor).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","pValueComment":"Stratified log-rank test stratified by age (18 - \\< 75, ≥ 75) and cytogenetic risk (intermediate, poor).","paramType":"Hazard Ratio (HR)","paramValue":"0.580","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.4","upperLimit":"12.7","value":"9.6"},{"groupId":"OG001","lowerLimit":"12.1","upperLimit":"18.7","value":"14.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"145"},{"groupId":"OG001","value":"286"}],"units":"Participants"}],"description":"OS is defined as the number of days from the date of randomization to the date of death. Log rank test was used to compare the OS distribution between two treatment arms. Cox regression was used to report the hazard ratio.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received venetoclax-matching placebo, orally, QD, from Day 1 to Day 28 of each 28 day cycle along with azacitidine 75 mg/m\\^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).","id":"OG000","title":"Group 2: Placebo + Azacitidine 75 mg/m^2"},{"description":"Participants received venetoclax 100 mg, once orally, on Day 1 of Cycle 1 followed by venetoclax 200 mg, once orally, on Day 2 of Cycle 1 and venetoclax 400 mg, orally, QD, from Day 3 to Day 28 of each 28-day cycle along with azacitidine 75 mg/m\\^2, SC or IV, QD for 7 days from Day 1 of each 28-day cycle until documented disease progression, unacceptable toxicity, withdrawal of consent, or other protocol criteria for discontinuation (whichever occurred first).","id":"OG001","title":"Group 2: Venetoclax 100 mg/200 mg/400 mg + Azacitidine 75 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set included all Group 2 participants randomized by IVRS/IWRS (exclude the open-label China safety cohort).","reportingStatus":"POSTED","timeFrame":"From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021)","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}